Work

Bdnf mRNA‐LNP Drives Nasal Epithelial BDNF Production and Improves Cognition in Aged and Alzheimer's Disease Mouse Models

Year: 2026
Type: article
Abstract: Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.
Language: English
Open Access status: gold
Estimated APC paid: $6,730
OpenAlex ID: W7155039114
FWCI:
Cites: 96
Cited by:
Related to: 10